p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro

World Journal of Gastroenterology

Volumn 13, Issue 5, 2007, Pages 683-691

  Zhao, Hong Chuan ^a   Zhang, Qi ^a   Yang, Yang ^a   Lu, Min Qiang ^a   Li, Hua ^a   Xu, Chi ^a   Chen, Gui Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Conditionally replicative adenovirus; Gene therapy; Hepatocellular carcinoma; Oncolytic virotherapy; p53 gene

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; ONCOLYTIC VIRUS; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; PROMOTER REGION; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 33846991645     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i5.683     Document Type: Article

References (35)

1. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108
2. Nemunaitis J, Edelman J. Selectively replicating viral vectors. Cancer Gene Ther 2002; 9: 987-1000
3. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502
4. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727
5. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-851
6. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003; 10: 1241-1247
7. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama G, Ide T. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995; 55: 2734-2736
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
9. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-783
10. Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 2000; 60: 2666-2672
11. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165-6171
12. Qi Z, Linhui P, Hongping W. Construction of CNHK500, a conditionally replicating adenovirus driven by the human telomerase reverse transcriptase promoter and hypoxia response promoter. Zhonghua Shiyan Waike Zazhi 2004; 21: 1366-1368
13. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, Stancou R, Badie C, Haddada H, Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999; 18: 5464-5472
14. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946
15. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376
16. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395-3399
17. Sangro B, Herraiz M, Prieto J. Gene therapy of neoplastic liver diseases. Int J Biochem Cell Biol 2003; 35: 135-148
18. Ohashi M, Kanai F, Tateishi K, Taniguchi H, Marignani PA, Yoshida Y, Shiratori Y, Hamada H, Omata M. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun 2001; 282:529-535
19. Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M, Fang G, Liu X, Wu M, Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004; 64: 5390-5397
20. Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World J Gastroenterol 2006; 12: 6085-6097
21. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 2004; 279: 348-355
22. Shay JW, Wright WE. Telomeres and telomerase: implications for cancer and aging. Radiat Res 2001; 155: 188-193
23. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Hypoxia-mediated tumour targeting. Gene Ther 2003; 10: 540-549
24. Su CQ, Sham J, Xue HB, Wang XH, Chua D, Cui ZF, Peng LH, Li LF, Jiang LH, Wu MC, Qian QJ. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol 2004; 130: 591-603
25. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002; 62: 2883-2889
26. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, Dbaibo GS, Hannun YA, Obeid LM. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004; 279: 20546-20554
27. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014
28. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-293
29. Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood 2004; 103: 2691-2698
30. Sah NK, Munshi A, Nishikawa T, Mukhopadhyay T, Roth JA, Meyn RE. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther 2003; 2: 1223-1231
31. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of NOR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283
32. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-6957
33. Ala-aho R, Grenman R, Seth P, Kahari VM. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 2002; 21: 1187-1195
34. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 2003; 422: 527-531
35. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J, Engeland K. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 2004; 23: 3376-3384